The biggest moving parts are pending reimbursement decisions in France, Italy and Spain …. And wether MITIGATE CV data is good enough to resubmit for German reimbursement.
If Denner gets control and can get these big 4 EU reimbursements in place in 2023 , he’ll stop expenses on other programs and sell this Co for the remaining years of EU exclusivity in 2024
JMO based my experience owning MDCO when Denner got control
News 
Market Data 
Discover 
AI
